LULucid Diagnostics Inc. LUCD · NASDAQ
$0.35 -6.76% (-$0.03)
- Market cap
- $72.1M
- Enterprise value
- $63.6M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 13.2x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -141.4%
- Gross margin
- -25.8%
- Net margin
- -959.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.12
- Free float
- 73.7%
About the company
Lucid Diagnostics Inc. is a biotechnology company focused on developing diagnostic technologies and tests. The company specializes in diagnostics and disease detection, particularly in the field of gastroenterology. Lucid Diagnostics develops advanced diagnostic tests and devices that enable precise and rapid determination of patients' conditions and identification of potential diseases. The company emphasizes research and development to provide the medical industry with innovative tools and technologies to improve diagnostics and patient care. Lucid Diagnostics aims to contribute to better health outcomes and quality of life for patients through its diagnostic innovations. Lucid Diagnostics Inc. shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focused on the development of diagnostic technologies with the potential to enhance medical care.
Sector
Healthcare
Industry
Medical - Devices
CEO
Lishan Aklog
Employees
82
Headquarters
New York City
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number